SOMERSET, N.J.--(BUSINESS WIRE)--Catalent Pharma Solutions, Inc. (“Catalent”) announced today that it has extended its offer to exchange up to $350,000,000 aggregate principal amount of its 7.875% Senior Notes due 2018 and the guarantees thereof, which have been registered under the Securities Act of 1933, as amended, for any and all of its outstanding 7.875% Senior Notes due 2018 and the guarantees thereof (the “Notes”), respectively, to 5:00 p.m., New York City time, on Monday, July 29, 2013, unless further extended.
The terms and conditions of the exchange offers are set forth in the prospectus dated June 26, 2013.
The exchange offers had been scheduled to expire at 11:59 p.m., New York City time, on Wednesday, July 24, 2013. As of 11:59 p.m., New York City time, on July 24, 2013, Catalent had been advised that $346.9 million in aggregate principal amount, or 99%, of outstanding unregistered Notes, had been validly tendered to the exchange agent by the holders thereof.
The exchange agent for the offer is The Bank of New York Mellon, 111 Sanders Creek Parkway, East Syracuse, New York 13057, Attention: Dacia Brown-Jones, Tel: 315-414-3349.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction where such an offering or sale would be unlawful.
Forward Looking Statements
This press release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”, “likely”, “may”, “will”, “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to update any forward-looking statements as a result of new information or future events or developments unless required by law.
About Catalent Pharma Solutions
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
